Cardiovascular Diabetology

1. Cardiovasc Diabetol11 Jun 2026

   Associations of metabolic score for insulin resistance and new-onset stroke in middle-aged and older adults: a national cohort study

   Cohort studyComplications

2. Cardiovasc Diabetol11 Jun 2026

   Estimated glucose disposal rate outperforms inflammation surrogate markers in predicting cardiometabolic multimorbidity among middle-aged and older adults

   Cohort studyT2D & other

3. Cardiovasc Diabetol11 Jun 2026

   Predicting subclinical atherosclerosis in adults with type 1 diabetes using cardiovascular risk models: a cross‑sectional study from Italy

   Cross-sectional studyT1D

4. Cardiovasc Diabetol10 Jun 2026

   Association of the C-reactive protein-triglyceride-glucose (CTI) index and its central obesity-modified derivatives with incident cardiometabolic multimorbidity: results from two prospective cohorts in China and England

   Cohort studyObesity

5. Cardiovasc Diabetol10 Jun 2026

   Increased epicardial adipose tissue area and radiodensity in sarcopenic obesity

   Cross-sectional studyObesity

6. Cardiovasc Diabetol8 Jun 2026

   Differential associations between novel triglyceride-glucose-obesity indices and incident stroke in individuals with early-stage cardiovascular-kidney-metabolic syndrome: a longitudinal cohort study

   Cohort studyObesity

7. Cardiovasc Diabetol7 Jun 2026

   Predictive value of the triglyceride glucose index-a body shape index (TyG-ABSI) for cardiovascular disease and its comparison with other TyG-related obesity indices: a study based on the China health and retirement longitudinal study (CHARLS) cohort

   Cohort studyObesity

8. Cardiovasc Diabetol6 Jun 2026

   Associations of cumulative exposure and dynamic trajectories of the combined atherogenic and frailty index with incident cardiometabolic multimorbidity: a longitudinal analysis based on the China Health and Retirement Longitudinal Study (CHARLS)

   Cohort studyLipids & liver

9. Cardiovasc Diabetol5 Jun 2026

   Association of 14 triglyceride-glucose (TyG)-related indices with new-onset cardiovascular disease in middle-aged and older adults: evidence from the CHARLS and ELSA aging cohorts

   Cohort studyT2D & other

10. Cardiovasc Diabetol3 Jun 2026

    Effects of adiposity, insulin resistance, and inflammation on cardiometabolic multimorbidity: insights from interaction analyses and metabolic phenotyping in the China health and retirement longitudinal study 2011–2018

    Cohort studyT2D & other

11. Cardiovasc Diabetol3 Jun 2026

    Systematic comparison of triglyceride-glucose (TYG)-index with other mortality predictive models in obese patients with different mortality rates

    Diagnostic or prognostic studyObesity

12. Cardiovasc Diabetol3 Jun 2026

    Association between C-reactive protein-triglyceride glucose related indices and all-cause and cardiovascular mortality in individuals with cardiovascular-kidney-metabolic syndrome

    Cohort studyLipids & liver

13. Cardiovasc Diabetol3 Jun 2026

    Adolescent obesity and risk of serious chronic morbidity and mortality in young adulthood: a systematic review of cohorts from national registries

    Meta-analysisObesity

14. Cardiovasc Diabetol2 Jun 2026

    Cardiac remodeling after bariatric surgery associates with systemic metabolic reprogramming: a longitudinal untargeted metabolomics study

    Cohort studyObesity

15. Cardiovasc Diabetol2 Jun 2026

    Composite C-reactive protein–triglyceride–glucose–adiposity indices and incident cardiovascular disease in the CHARLS cohort: a prospective cohort study

    Cohort studyObesity

16. Cardiovasc Diabetol1 Jun 2026

    Unraveling ‘F’ factor: towards a genetic-clinical framework for the musculoskeletal-heart crosstalk in metabolic aging

    Cohort studyT2D & other

17. Cardiovasc Diabetol1 Jun 2026

    Estimated glucose disposal rate outperforms thirteen other insulin resistance indices in predicting new-onset cardiometabolic multimorbidity: a longitudinal study from the china health and retirement longitudinal study (CHARLS) and cross-sectional replication from the national health and nutrition examination survey (NHANES)

    Cross-sectional studyT2D & other

18. Cardiovasc Diabetol31 May 2026

    Associations of the atherogenic index of plasma and its modified indices with the incidence and progression of cardiovascular-liver-metabolic multimorbidity: a prospective cohort study from UK Biobank

    Cohort studyLipids & liver

19. Cardiovasc Diabetol28 May 2026

    Large-scale multi-omics enhance risk prediction for type 2 diabetes

    Diagnostic or prognostic studyT2D & other

20. Cardiovasc Diabetol28 May 2026

    Incidence, risk factors and sequelae of long/post-COVID in people with diabetes compared to people without diabetes in Germany (longcovid-diab): a study protocol

    Trial designT2D & other

21. Cardiovasc Diabetol26 May 2026

    Changes in cardiac myosin acetylation disrupt the super-relaxed state in genotype-negative hypertrophic cardiomyopathy with type 2 diabetes

    Mechanistic studyT2D & other

22. Cardiovasc Diabetol26 May 2026

    Exerkine dysregulation links visceral adiposity to skeletal muscle impairment in end-stage heart failure with reduced ejection fraction: proteomic evidence for a cardio–adipose–muscle axis

    Cross-sectional studyComplications

23. Cardiovasc Diabetol26 May 2026

    Associations of the combined C-reactive protein-triglyceride glucose index and frailty index in different dimensions with incident stroke among individuals with stages 0–3 cardiovascular-kidney-metabolic syndrome

    Cohort studyLipids & liver

24. Cardiovasc Diabetol25 May 2026

    Effects of semaglutide on mortality, cardiovascular, and kidney outcomes across the cardio-kidney-metabolic continuum: a systematic review and meta-analysis

    Meta-analysisT2D & other

25. Cardiovasc Diabetol17 May 2026

    Predicting cardiovascular death in overweight/obese people with prediabetes using machine learning—a proof-of-concept study

    Diagnostic or prognostic studyT2D & other

26. Cardiovasc Diabetol17 May 2026

    Joint association of atherogenic index of plasma (AIP) and body roundness index (BRI) with cardiometabolic multimorbidity in adults in Guangzhou, China

    Cross-sectional studyT2D & other

27. Cardiovasc Diabetol17 May 2026

    Predictive value of the combined cholesterol, high-density lipoprotein, glucose and frailty indices for cardiometabolic multimorbidity incidence: evidence from a national prospective cohort study

    Cohort studyT2D & other

28. Cardiovasc Diabetol17 May 2026

    Comparative prognostic value of TyG index and TyG-BMI for 90-day all-cause mortality in critically ill older adults with ASCVD: a machine learning analysis of the MIMIC-IV database

    Cohort studyLipids & liver

29. Cardiovasc Diabetol17 May 2026

    Cardiovascular, limb, and kidney effects of SGLT2 inhibitors in patients with peripheral artery disease: a systematic review and meta-analysis of randomized controlled trial data

    Meta-analysisT2D & other

30. Cardiovasc Diabetol16 May 2026

    Longitudinal associations of cumulative and repeated-measure patterns of insulin resistance surrogate indices with biological age acceleration and incident cardiovascular disease across cardiovascular-kidney-metabolic syndrome stages 0–3: evidence from CHARLS 2011–2020

    Cohort studyT2D & other

31. Cardiovasc Diabetol14 May 2026

    Drug targets for lipid modification and risk of type 2 diabetes: a cis-Mendelian randomization study

    Research articleT2D & other

32. Cardiovasc Diabetol11 May 2026

    Evaluation of the lipid accumulation product for MASLD risk stratification in type 2 diabetes: establishing sex-specific thresholds and clinical utility

    Diagnostic or prognostic studyT2D & other

33. Cardiovasc Diabetol11 May 2026

    Association of cumulative exposure and dynamic trajectories of the C-reactive protein-triglyceride-glucose and its modified indices with cardiovascular disease in individuals with cardiovascular-kidney-metabolic syndrome stages 0–3: a longitudinal analysis based on CHARLS

    Cohort studyObesity

34. Cardiovasc Diabetol9 May 2026

    Integrative proteogenomic and observational analysis identifies potential biomarkers for latent autoimmune diabetes in adults

    Cohort studyT1D

35. Cardiovasc Diabetol9 May 2026

    Multi-omics uncovers the pleiotropic genetic mechanisms linking MASLD and cardiometabolic syndromes

    Research articleLipids & liver

36. Cardiovasc Diabetol6 May 2026

    Associations of nine insulin resistance-related indices with the incidence and progression of cardiovascular-liver-metabolic multimorbidity: a large prospective cohort study

    Cohort studyLipids & liver

37. Cardiovasc Diabetol6 May 2026

    CVOT Summit Report 2025: advances along the cardiovascular–kidney–metabolic disease continuum

    Research articleT2D & other

38. Cardiovasc Diabetol4 May 2026

    Phenotypic clustering of newly diagnosed type 2 diabetes in a Mediterranean cohort

    Cohort studyT2D & other

39. Cardiovasc Diabetol3 May 2026

    The association between triglyceride glucose-frailty index and cardiometabolic multimorbidity among Chinese middle-aged and older adults: a national prospective cohort study

    Cohort studyLipids & liver

40. Cardiovasc Diabetol2 May 2026

    Joint association of atherogenic index of plasma and estimated glucose disposal rate with new-onset cardiovascular disease risk in individuals with cardiovascular–kidney–metabolic syndrome stages 0–3: a 9-year nationwide prospective cohort study

    Cohort studyT2D & other

All 1,291 Briefs in ExploreShowing Briefs 81–120 of 1,291, newest first